Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Development of Human Microbiota

Development of Human Microbiota

The human microbiota begins developing at birth and undergoes continual change as we age. Infancy marks a critical period of microbial sensitivity, offering a “window of opportunity” during which beneficial microbes help mature the immune system. By age three, children typically develop a more stable and diverse microbial community. Newborns acquire microbes from their immediate environment; vaginal delivery favors maternal vaginal microbes, while cesarean births favor microbes from the skin...

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

Microorganisms in Medicine and Therapeutics

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Incidence and outcomes for colonization of multidrug-resistance organisms (MDROs) among patients undergoing elective orthopedic surgery.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026

Same author

Risk factors for infections after urological procedures among patients with negative urine culture screening.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026

Same author

Optimizing Micafungin Dosing in Patients with Critically Ill Candidemia and Trends of <i>Candida</i> Species Causing Bloodstream Infections in a Tertiary Hospital in Thailand: A Monte Carlo Simulation Approach.

Drug design, development and therapy·2025

Same author

The effectiveness of augmented reality handouts for learning microbiology in medical students.

Journal of microbiology & biology education·2025

Same author

Impact of Pharmacist-Led Multidisciplinary Team to Attain Targeted Vancomycin Area under the Curved Monitoring in a Tertiary Care Center in Thailand.

Antibiotics (Basel, Switzerland)·2023

Same author

Real-life effectiveness of COVID-19 vaccine during the Omicron variant-dominant pandemic: how many booster doses do we need?

Emerging microbes & infections·2023

Search research articles

Related Experiment Video

Updated: May 12, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Fecal Bacteriotherapy for Recurrent Clostridium difficile Infection: What's Old Is New Again?

Nuntra Suwantarat¹, David A Bobak

¹Division of Infectious Diseases and HIV Medicine, Case School of Medicine, University Hospitals Case Medical Center, 11100 Euclid Avenue, Cleveland, OH, 44106, USA, nuntra.suwantarat@case.edu.

Current Infectious Disease Reports

|April 4, 2013

Summary

Fecal microbiota transplantation, a therapy for recurrent Clostridium difficile infection (CDI), shows promise as a safe and effective treatment. While not yet standard, its use is increasing in clinical practice.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Related Experiment Videos

Last Updated: May 12, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Area of Science:

Gastroenterology
Infectious Diseases
Microbiology

Background:

Recurrent Clostridium difficile infection (CDI) presents a significant clinical challenge.
Traditional antibiotic therapies for CDI have limitations, driving interest in alternative treatments.

Purpose of the Study:

To review the current evidence and clinical interest in fecal bacteriotherapy (FMT) as a treatment for recurrent CDI.
To assess the safety and efficacy of FMT based on emerging studies.

Main Methods:

Review of recent studies and clinical observations regarding fecal bacteriotherapy for CDI.
Analysis of available evidence on the safety and effectiveness of the procedure.

Main Results:

Fecal bacteriotherapy, also known as fecal microbiota transplantation, is gaining attention for managing recurrent CDI.
Preliminary evidence suggests FMT is generally safe and effective for selected patients.
Despite concerns regarding efficacy and potential complications, its adoption is growing.

Conclusions:

Fecal bacteriotherapy is a promising, non-antibiotic approach for recurrent CDI.
Further well-controlled trials are needed, but FMT is increasingly used in clinical settings.